MedPath

Phenoxymethylpenicillin

Generic Name
Phenoxymethylpenicillin
Brand Names
Pen VK
Drug Type
Small Molecule
Chemical Formula
C16H18N2O5S
CAS Number
87-08-1
Unique Ingredient Identifier
Z61I075U2W
Background

Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK. It is a phenoxymethyl analog of Penicillin G, or benzylpenicillin. An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, skin, and soft tissues caused by penicillin G­-sensitive microorganisms. Phenoxymethylpenicillin has also be used in some cases as prophylaxis against susceptible organisms. While there have been no controlled clinical efficacy studies that were conducted, phenoxymethylpenicillin has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract, except for those who are at an elevated risk for endocarditis.

Indication

Indicated for the treatment of mild to moderately severe infections due to penicillin G­-sensitive microorganisms, with the use of bacteriological studies (including sensitivity tests) and clinical response.

Phenoxymethylpenicillin may be used for the treatment of:

Off-label

Indicated for use as prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract.

Associated Conditions
Actinomycosis, Animal bite, Anthrax, Bacterial Endocarditis, Bacterial Infections, Community Acquired Pneumonia (CAP), Erythema Chronicum Migrans, Gingivitis, Necrotizing Ulcerative, Lower Respiratory Tract Infection (LRTI), Scarlet Fever, Skin and Subcutaneous Tissue Bacterial Infections, Streptococcal Pharyngitis, Tonsillitis streptococcal, Mild Otitis media, Mild bacterial upper respiratory tract infections, Moderate Otitis media, Moderate bacterial upper respiratory tract infections, Prophylaxis of Rheumatic fever
Associated Therapies
-
pmc.ncbi.nlm.nih.gov
·

Ruxolitinib for Myelofibrosis – An Update of Its Clinical Effects

Ruxolitinib, a JAK1/JAK2 inhibitor, significantly improves splenomegaly and symptoms in intermediate-2 or high-risk myelofibrosis patients, as shown in COMFORT-I and COMFORT-II trials. Despite dose-dependent anemia and thrombocytopenia, adverse effects were manageable. Long-term data confirm durable benefits across patient subgroups, with potential survival improvement.
© Copyright 2025. All Rights Reserved by MedPath